He Yongquan, Fu Weihui, Cao Kangli, He Qian, Ding Xiangqing, Chen Jian, Zhu Lingyan, Chen Tianyue, Ding Longfei, Yang Yu, Zhu Cuisong, Yuan Songhua, Li Zejun, Zhao Chen, Zhang Xiaoyan, Xu Jianqing
Shanghai Public Health Clinical Center and Institutes of Biomedical Sciences, Shanghai Medical College, Fudan University, Shanghai 201508, P. R. China.
Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai 200241, P. R. China.
Sci Signal. 2020 Apr 7;13(626):eaaz3381. doi: 10.1126/scisignal.aaz3381.
Type I interferons (IFNs) are the first line of defense against viral infection. Using a mouse model of influenza A virus infection, we found that IFN-κ was one of the earliest responding type I IFNs after infection with H9N2, a low-pathogenic avian influenza A virus, whereas this early induction did not occur upon infection with the epidemic-causing H7N9 virus. IFN-κ efficiently suppressed the replication of various influenza viruses in cultured human lung cells, and chromodomain helicase DNA binding protein 6 (CHD6) was the major effector for the antiviral activity of IFN-κ, but not for that of IFN-α or IFN-β. The induction of CHD6 required both of the type I IFN receptor subunits IFNAR1 and IFNAR2, the mitogen-activated protein kinase (MAPK) p38, and the transcription factor c-Fos but was independent of signal transducer and activator of transcription 1 (STAT1) activity. In addition, we showed that pretreatment with IFN-κ protected mice from lethal influenza viral challenge. Together, our findings identify an IFN-κ-specific pathway that constrains influenza A virus and provide evidence that IFN-κ may have potential as a preventative and therapeutic agent against influenza A virus.
I型干扰素(IFNs)是抵御病毒感染的第一道防线。利用甲型流感病毒感染的小鼠模型,我们发现IFN-κ是感染低致病性甲型禽流感病毒H9N2后最早产生反应的I型干扰素之一,而在感染致病性H7N9病毒时则不会出现这种早期诱导现象。IFN-κ能有效抑制多种流感病毒在培养的人肺细胞中的复制,并且染色质结构域解旋酶DNA结合蛋白6(CHD6)是IFN-κ抗病毒活性的主要效应因子,但不是IFN-α或IFN-β抗病毒活性的主要效应因子。CHD6的诱导需要I型干扰素受体亚基IFNAR1和IFNAR2、丝裂原活化蛋白激酶(MAPK)p38以及转录因子c-Fos,但不依赖于信号转导和转录激活因子1(STAT1)的活性。此外,我们还表明,用IFN-κ预处理可保护小鼠免受致命性流感病毒攻击。总之,我们的研究结果确定了一条限制甲型流感病毒的IFN-κ特异性途径,并提供了证据表明IFN-κ可能具有作为预防和治疗甲型流感病毒药物的潜力。